[go: up one dir, main page]

PE119199A1 - Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica - Google Patents

Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica

Info

Publication number
PE119199A1
PE119199A1 PE1998000882A PE00088298A PE119199A1 PE 119199 A1 PE119199 A1 PE 119199A1 PE 1998000882 A PE1998000882 A PE 1998000882A PE 00088298 A PE00088298 A PE 00088298A PE 119199 A1 PE119199 A1 PE 119199A1
Authority
PE
Peru
Prior art keywords
rna
infection
chronic hepatitis
alpha
patients
Prior art date
Application number
PE1998000882A
Other languages
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE119199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE119199A1 publication Critical patent/PE119199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE AL USO JUNTO O SEPARADO DE a)RIBAVIRINA UTILIZANDOSE 400-1200 mg/DIA; b)INTERFERON ALFA UTILIZANDOSE DE 2-10 MILLONES UI; PARA LA FABRICACION DE UNA COMPOSICION QUE PUEDE SER UTIL PARA TRATAR UNA INFECCION POR HEPATITIS C CRONICA Y ERRADICAR EL VHC-ARN DETECTABLE, O UNA CARGA VIRAL MAYOR DE 2 MILLONES POR MILILITRO DE SUERO, MEDIDA POR PRC CUANTITATIVA DEL VHC-ARN. EL INTERFERON ALFA ES DE PREFERENCIA INTERFERON ALFA-2a, INTERFERON ALFA 2-b, INTERFERON ALFA CONSENSUAL, UN PRODUCTO DE INTERFERON ALFA PURIFICADO, INTERFERON ALFA PEGILADO
PE1998000882A 1997-09-21 1998-09-16 Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica PE119199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22

Publications (1)

Publication Number Publication Date
PE119199A1 true PE119199A1 (es) 1999-12-01

Family

ID=27130070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000882A PE119199A1 (es) 1997-09-21 1998-09-16 Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica

Country Status (24)

Country Link
EP (3) EP1317929A3 (es)
JP (1) JPH11152231A (es)
KR (1) KR20010024188A (es)
CN (1) CN1250283C (es)
AR (1) AR013497A1 (es)
AT (2) ATE206618T1 (es)
AU (1) AU749924B2 (es)
BR (1) BR9812484A (es)
CA (1) CA2245938C (es)
CO (1) CO4970691A1 (es)
DE (2) DE69810822T2 (es)
DK (2) DK0903148T3 (es)
ES (2) ES2162393T3 (es)
HK (1) HK1041440B (es)
HU (1) HUP0100092A3 (es)
IL (1) IL134428A0 (es)
MY (1) MY117781A (es)
NO (1) NO20001437D0 (es)
NZ (1) NZ502740A (es)
PE (1) PE119199A1 (es)
PT (1) PT903148E (es)
SK (1) SK3922000A3 (es)
TW (1) TW568787B (es)
WO (1) WO1999015194A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ES2172288T3 (es) * 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
WO2000037097A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
SI1330468T1 (sl) 2000-09-18 2007-10-31 Serono Lab Ĺ˝veplovi analogi 21-hidroksi-6,19-oksido-progesterona (21oh-6op) za zdravljenje preseĺ˝ka glukokortikoidov
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
JP2005533824A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
PL2604620T5 (pl) 2003-05-30 2024-10-14 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydu
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009015336A2 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
SG11201400664WA (en) 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
WO1999015194A1 (en) 1999-04-01
HUP0100092A2 (hu) 2001-05-28
PT903148E (pt) 2002-02-28
HK1016505A1 (en) 1999-11-05
HUP0100092A3 (en) 2002-03-28
EP1317929A3 (en) 2003-07-02
EP0903148B1 (en) 2001-10-10
DK1136075T3 (da) 2003-04-28
CO4970691A1 (es) 2000-11-07
CA2245938C (en) 2003-07-15
CN1271292A (zh) 2000-10-25
MY117781A (en) 2004-08-30
KR20010024188A (ko) 2001-03-26
AU749924B2 (en) 2002-07-04
AR013497A1 (es) 2000-12-27
TW568787B (en) 2004-01-01
EP1317929A2 (en) 2003-06-11
DE69801970D1 (de) 2001-11-15
AU9473798A (en) 1999-04-12
DE69810822D1 (de) 2003-02-20
ATE230999T1 (de) 2003-02-15
NO20001437L (no) 2000-03-20
BR9812484A (pt) 2000-09-19
EP1136075A1 (en) 2001-09-26
IL134428A0 (en) 2001-04-30
EP1136075B1 (en) 2003-01-15
ES2186660T3 (es) 2003-05-16
NO20001437D0 (no) 2000-03-20
CN1250283C (zh) 2006-04-12
HK1041440B (en) 2003-09-05
NZ502740A (en) 2002-10-25
CA2245938A1 (en) 1999-03-21
EP0903148A3 (en) 1999-04-28
EP0903148A2 (en) 1999-03-24
JPH11152231A (ja) 1999-06-08
DE69801970T2 (de) 2002-06-13
DK0903148T3 (da) 2001-12-17
ATE206618T1 (de) 2001-10-15
HK1041440A1 (en) 2002-07-12
SK3922000A3 (en) 2000-10-09
ES2162393T3 (es) 2001-12-16
DE69810822T2 (de) 2003-11-20

Similar Documents

Publication Publication Date Title
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
CO4940414A1 (es) Terapia de interferones polietilenglicol modificados
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
MXPA02006679A (es) Composicion farmaceutica.
NZ330784A (en) Modulation of th1/th2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0108997A (pt) Terapia imune adjuvante para hiv
MD990258A (en) Method of treatment of the acute viral hepatitis B
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
AR029337A1 (es) Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
AU5535498A (en) Treatment of HIV positive patients
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
Mascolini Protease inhibitor update: treatment combination strategies
ATE269063T1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
Highleyman Twice-daily indinavir dosing not recommended
ECSP003462A (es) Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k)
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
PE20010226A1 (es) Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica
Simmons Dressing up your virus: a new outfit for HIV

Legal Events

Date Code Title Description
FC Refusal